IL1RL2 and psoriasis: Furthermore, psoriatic lesional skin improves after inhibiting IL-36R [100], and treating psoriasis patients with etanercept (an anti-TNF-α drug) leads to clinical improvement in accordance with significantly decreased IL-36 procytokine, IL-36R and IL-36Ra mRNA levels [92].